Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

453
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
453
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

463
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
463
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
189
Hypersensitivities01:30

Hypersensitivities

1.0K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
1.0K
Skin Cancer01:30

Skin Cancer

4.5K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.5K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Epidemiology of atopic dermatitis.

Journal of the American Academy of Dermatology·2026
Same author

The Burden of Eczema (Atopic Dermatitis) in Canadian Adults: A Cross-Sectional Survey.

Journal of cutaneous medicine and surgery·2026
Same author

Narrowband vs broadband ultraviolet B phototherapy for adults with moderate-to-severe atopic dermatitis: a randomized controlled trial.

The British journal of dermatology·2026
Same author

Population-Based and Routinely Collected Health Data Studies of Immunobullous Diseases: A Scoping Review.

Journal of cutaneous medicine and surgery·2026
Same author

Guidelines of care for the management of atopic dermatitis in pediatric patients.

Journal of the American Academy of Dermatology·2026
Same author

Guidelines of care for the primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitis.

Journal of the American Academy of Dermatology·2026

Video Experimental Relacionado

Updated: Sep 10, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K

Nuevos tratamientos tópicos y sistémicos para la dermatitis atópica

Sara Mirali1, Aaron M Drucker1,2

  • 1Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
|August 21, 2025
PubMed
Resumen

Las nuevas terapias dirigidas ofrecen tratamientos más seguros y efectivos para la dermatitis atópica, una condición inflamatoria de la piel. Esta revisión abarca los inhibidores tópicos de la PDE4, los inhibidores JAK y los biológicos, que mejoran los resultados de los pacientes.

Más Videos Relacionados

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.8K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K

Videos de Experimentos Relacionados

Last Updated: Sep 10, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.8K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K

Área de la Ciencia:

  • Dermatología
  • Inmunología
  • Farmacología

Sus antecedentes:

  • La dermatitis atópica es una enfermedad inflamatoria crónica de la piel caracterizada por picazón y recidivas.
  • Los tratamientos tradicionales para la dermatitis atópica a menudo implicaban una amplia inmunosupresión, lo que limitaba la aplicación a largo plazo.
  • La necesidad de opciones terapéuticas más seguras y más específicas es crítica.

Objetivo del estudio:

  • Revisar la eficacia y la seguridad de los nuevos agentes terapéuticos para la dermatitis atópica.
  • Proporcionar una visión general de los tratamientos emergentes más allá de las opciones inmunosupresoras en general.

Principales métodos:

  • Revisión de la literatura de estudios recientes sobre el tratamiento de la dermatitis atópica.
  • Análisis de los datos de ensayos clínicos para nuevas clases terapéuticas.
  • Síntesis de los perfiles de seguridad y eficacia de los nuevos agentes.

Principales resultados:

  • Los inhibidores tópicos de la fosfodiesterasa 4 (PDE4) muestran efectos antiinflamatorios dirigidos.
  • Los agonistas tópicos del receptor de hidrocarburos de arilo ofrecen un nuevo mecanismo para el manejo de la condición de la piel.
  • Los inhibidores sistémicos y tópicos de Janus kinase (JAK) muestran una eficacia significativa en el tratamiento de la dermatitis atópica.
  • Las terapias biológicas proporcionan inmunomodulación dirigida para la dermatitis atópica de moderada a grave.

Conclusiones:

  • Las nuevas terapias dirigidas, incluidos los inhibidores de PDE4, los inhibidores de JAK y los biológicos, representan un avance significativo en el tratamiento de la dermatitis atópica.
  • Estos nuevos agentes ofrecen mejores perfiles de seguridad en comparación con los inmunosupresores tradicionales, lo que permite un manejo más sostenido.
  • El desarrollo de terapias dirigidas promete un mejor control a largo plazo y una mejor calidad de vida para los pacientes con dermatitis atópica.